Global Hepatitis D Virus (HDV) Infection Market By Clinical Trails (Pre-Clinical and Phase I, Phase II, Phase III), By Clinical Entities (Acute HBV/HDV coinfection, Acute HDV superinfection of a Chronic HBV carrier, Chronic HDV infection), By Age (Below 20 years, 21 – 35 years, 36 – 50 Years, above 50), By Application (Hospitals, specialty Clinics, Research Centers), By Region (North America (U.S., Canada, Mexico, Rest Of North America), Europe (France, The UK, Spain, Germany, Italy, Denmark, Finland, Iceland, Sweden, Norway, Belgium, The Netherlands, Luxembourg, Rest of Europe), Asia Pacific (China, Japan, India, New Zealand, Australia, South Korea, Southeast Asia, Indonesia, Thailand, Malaysia, Singapore, Rest of Southeast Asia, Rest of Asia Pacific, Middle East & Africa (Saudi Arabia, UAE, Egypt, Kuwait, South Africa, Rest of Middle East & Africa) Latin America (Brazil, Argentina, Rest of Latin America)) - Global Insights, Growth, Size, Comparative Analysis, Trends and Forecast, 2021 – 2029
Industry Trends
Hepatitis D is also referred to as "delta hepatitis." It is an infection of the liver caused by the hepatitis D virus (HDV). Hepatitis D virus (HDV) infection occurs when people become infected with both hepatitis B and D at the same time (co-infection) or after being infected with hepatitis B first (superinfection). Because of the faster progression of liver-related death and hepatocellular carcinoma, the combination of HDV and HBV infection is considered to be the most severe form of chronic viral hepatitis. Populations that are highly probable to have HBV and HDV co-infection involve indigenous populations, recipients of hemodialysis, and people who inject drugs. There has been a significant increase in the number of Hepatitis D cases in the recent years. It's spreading at a tremendous rate. For Hepatitis D Virus (HDV) Infection, the government is developing evidence-based policy, raising awareness, and promoting market partnerships, which is contributing for the growth of the Hepatitis D virus (HDV) infection market over the forecast period. According to a 2020 study published in the Journal of Hepatology in collaboration with WHO, hepatitis D virus (HDV) covers approximately 5% of people worldwide.
The most commonly used treatment for hepatitis D virus infection is pegylated interferon-alpha and is linked to a lower risk of disease development. This medicine has serious side effects and should not be used in patients who have decompensated cirrhosis, active mental illnesses, or autoimmune diseases. Major market participants are expanding their product portfolio for the treatment of Hepatitis D Virus, which is contributing for the industry's growth. Alnylam Pharmaceuticals, Inc., a prominent RNAi therapeutics business, for instance, revealed that it has extended its hepatic infectious disease pipeline. The firm announced the addition of ALN-HDV, an RNAi therapy targeting the hepatitis delta virus (HDV) genome, which is under development for the treatment of HDV infection. It has also added ALN-PDL, an RNAi therapy that is in development for the treatment of chronic liver infections that targets hepatocyte-expressed programmed death-ligand 1 (PD-L1). Furthermore, enhanced potential of drug discovery innovation in the near future will present new opportunities for market participants in the Hepatitis D virus (HDV) infection market to flourish.
The study analyses the market in terms of revenue across all the major regions, which have been bifurcated into countries.
Global Hepatitis D Virus (HDV) Infection Market Revenue & Forecast, (US$ Million), 2015 – 2029
Clinical Trails Outlook:
Based on clinical trails, the global hepatitis D virus (HDV) infection market has been primarily segmented into pre-clinical and phase I, phase II, and phase III. According to the Hepatitis B Foundation, seven medicines are now being evaluated in clinical studies for their efficacy against the hepatitis D virus (HDV). Chronic Hepatitis D virus (HDV) infection is a rapidly progressive liver disease with increased liver-related mortality and hepatocellular carcinoma. As a result, major pharmaceutical companies are increasing research and development activities for the development of drugs such as Replicor's lead NAP compound, REP 2139, which has been shown to be effective against both HBV and HDV infection in clinical trials. REP 2139 efficiently prevents the assembly and release of HBV SVPs, which use the same processes as HDV for secretion. Furthermore, REP 2139 has a powerful and direct antiviral effect on HDV replication that differs from its effects on SVP assembly and release.
Clinical Entities Outlook:
Based on clinical entities, the global hepatitis D virus (HDV) infection market has been classified into acute HBV/HDV coinfection, acute hdv superinfection of a chronic hbv carrier, and chronic HDV infection. HBV/HDV co-infection occurs when an individual is infected with both HBV and HDV at the same time, whereas HDV superinfection happens when a person who is already chronically infected with HBV becomes infected with HDV. Although acute HBV/HDV coinfection can clear, HDV superinfection can cause rapid development of the pre-existing HBV infection, terminating liver cirrhosis and failure. These results occur in 70%–80% of persons with chronic HBV/HDV infection within 5–10 years, and in 15% within 1–2 years. In adults, HDV/HBV coinfection is often transient and self-limiting, with the same rate of progression to chronicity as HBV monoinfection i.e., less than 5 percent.
Age Outlook:
Based on age, the global hepatitis D virus (HDV) infection market has been classified into below 20 years, 21 – 35 years, 36 – 50 years, and above 50. According to data from the US National Library of Medicine, young adults between the ages of 18 and 25 who were infected with HDV have faced a moderate to severe risk of disease progression. Cirrhosis had already developed in almost one-third of the patients, showing the disease's aggressiveness.
Application Outlook:
Based on application, the global hepatitis D virus (HDV) infection market has been classified into hospitals, specialty clinics, and research centers. Among these applications, the research center segment is projected to account for the largest share of the market during the forecast period, owing to increased research on the development of drugs against the hepatitis D virus in both developed and developing economies, as well as increased research funding.
Region Outlook:
Based on regions, North America accounted for the largest share in the global hepatitis D virus (HDV) infection market due to higher healthcare spending for drug development. The presence of major players in the North American region is expected to contribute to the growth of the region. Furthermore, major economies such as the United States, Canada, and Mexico are contributing for technological improvement in research and development. HDV infection is uncommon in the United States, where most instances occur among people who migrate or travel to the country from HDV-endemic countries.
Competitive Landscape Outlook:
The report provides both, qualitative and quantitative research of hepatitis D virus (HDV) infection market, as well as provides comprehensive insights and development methods adopted by the key contenders. The report also offers extensive research on the key players in this market and details on the competitiveness of these players. Key business strategies such as mergers and acquisitions (M&A), affiliations, collaborations, and contracts adopted by these major market participants are also recognized and analyzed in the report. For each company, the report studies their global presence, competitors, service offerings and specification amongst others.
Some of the players operating in the hepatitis D virus (HDV) infection market:
- Alnylam Pharmaceuticals, Inc.
- EigerBioPharmaceuticals
- Gilead Sciences, Inc.
- Janssen Global Services, LLC
- Replicor
- Other Market participants
Global Hepatitis D Virus (HDV) Infection Market:
- By Clinical Trails
- Pre-Clinical and Phase I
- Phase II
- Phase III
- By Clinical Entities
- Acute HBV/HDV coinfection
- Acute HDV superinfection of a Chronic HBV carrier
- Chronic HDV infection
- By Age
- Below 20 years
- 21 – 35 years
- 36 – 50 Years
- Above 50
- By Application
- Hospitals
- Specialty Clinics
- Research Centers
- By Region
- North America
- U.S.
- Canada
- Mexico
- Rest of North America
- Europe
- France
- The UK
- Spain
- Germany
- Italy
- Nordic Countries
- Denmark
- Finland
- Iceland
- Sweden
- Norway
- Benelux Union
- Belgium
- The Netherlands
- Luxembourg
- Rest of Europe
- Asia Pacific
- China
- Japan
- India
- New Zealand
- Australia
- South Korea
- Southeast Asia
- Indonesia
- Thailand
- Malaysia
- Singapore
- Rest of Southeast Asia
- Rest of Asia Pacific
- Middle East & Africa
- Saudi Arabia
- UAE
- Egypt
- Kuwait
- South Africa
- Rest of Middle East & Africa
- Latin America
- Brazil
- Argentina
- Rest of Latin America
- North America
Table of Contents
1. Market Scope
1.1. Market Segmentation
1.2. Years Considered
1.2.1. Forecast Years: 2021
– 2029
2. Key Target Audiences
3. Research Methodology
3.1. Primary Research
3.1.1. Research
Questionnaire
3.1.2. Global Percentage
Breakdown
3.1.3. Primary Interviews:
Key Opinion Leaders (KOLs)
3.2. Secondary Research
3.2.1. Paid Databases
3.2.2. Secondary Sources
3.3. Market Size
Estimates
3.3.1. Top-Down Approach
3.3.2. Bottom-Up Approach
3.4. Data Triangulation
Methodology
3.5. Research Assumptions
4. Recommendations and Insights from AMI’s Perspective**
5. Holistic Overview of Hepatitis D Virus (HDV)
Infection Market
6. Market Synopsis: Hepatitis D Virus (HDV) Infection Market
7. Hepatitis D Virus (HDV) Infection Market
Analysis: Qualitative Perspective
7.1. Introduction
7.1.1. Product Definition
7.1.2. Industry Development
7.2. Market Dynamics
7.2.1. Drivers
7.2.2. Restraints
7.2.3. Opportunities
7.3. Trends in Hepatitis
D Virus (HDV) Infection Market
7.4. Market Determinants
Radar Chart
7.5. Macro-Economic and
Micro-Economic Indicators: Hepatitis D Virus (HDV) Infection Market
7.6. Porter’s Five Force Analysis
8.
Global Hepatitis D Virus (HDV)
Infection Market Analysis and Forecasts,
2021 – 2029
8.1. Overview
8.1.1. Global Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
8.2. Global Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
8.2.1. Pre-Clinical and Phase I
8.2.1.1.
Definition
8.2.1.2.
Market Forecast, 2021 - 2029
8.2.1.3.
Compound Annual Growth Rate
(CAGR)
8.2.1.4.
Regional Bifurcation
8.2.1.4.1.
North America
8.2.1.4.1.1. Market Forecast,
2021 - 2029
8.2.1.4.2.
Europe
8.2.1.4.2.1. Market Forecast,
2021 - 2029
8.2.1.4.3.
Asia Pacific
8.2.1.4.3.1. Market Forecast,
2021 - 2029
8.2.1.4.4.
Middle East and Africa
8.2.1.4.4.1. Market Forecast,
2021 - 2029
8.2.1.4.5.
Latin America
8.2.1.4.5.1. Market Forecast,
2021 - 2029
8.2.2. Phase II
8.2.2.1.
Definition
8.2.2.2.
Market Forecast, 2021 - 2029
8.2.2.3.
Compound Annual Growth Rate
(CAGR)
8.2.2.4.
Regional Bifurcation
8.2.2.4.1.
North America
8.2.2.4.1.1. Market Forecast,
2021 - 2029
8.2.2.4.2.
Europe
8.2.2.4.2.1. Market Forecast,
2021 - 2029
8.2.2.4.3.
Asia Pacific
8.2.2.4.3.1. Market Forecast,
2021 - 2029
8.2.2.4.4.
Middle East and Africa
8.2.2.4.4.1. Market Forecast,
2021 - 2029
8.2.2.4.5.
Latin America
8.2.2.4.5.1. Market Forecast,
2021 - 2029
8.2.3. Phase III
8.2.3.1.
Definition
8.2.3.2.
Market Forecast, 2021 - 2029
8.2.3.3.
Compound Annual Growth Rate
(CAGR)
8.2.3.4.
Regional Bifurcation
8.2.3.4.1.
North America
8.2.3.4.1.1. Market Forecast,
2021 - 2029
8.2.3.4.2.
Europe
8.2.3.4.2.1. Market Forecast,
2021 - 2029
8.2.3.4.3.
Asia Pacific
8.2.3.4.3.1. Market Forecast,
2021 - 2029
8.2.3.4.4.
Middle East and Africa
8.2.3.4.4.1. Market Forecast,
2021 - 2029
8.2.3.4.5.
Latin America
8.2.3.4.5.1. Market Forecast, 2021
- 2029
8.3. Key Segment for
Channeling Investments
8.3.1. By Clinical Trails
9.
Global Hepatitis D Virus (HDV)
Infection Market Analysis and Forecasts,
2021 – 2029
9.1. Overview
9.2. Global Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
9.2.1. Acute HBV/HDV
coinfection
9.2.1.1.
Definition
9.2.1.2.
Market Forecast, 2021 - 2029
9.2.1.3.
Compound Annual Growth Rate
(CAGR)
9.2.1.4.
Regional Bifurcation
9.2.1.4.1.
North America
9.2.1.4.1.1. Market Forecast,
2021 - 2029
9.2.1.4.2.
Europe
9.2.1.4.2.1. Market Forecast,
2021 - 2029
9.2.1.4.3.
Asia Pacific
9.2.1.4.3.1. Market Forecast,
2021 - 2029
9.2.1.4.4.
Middle East and Africa
9.2.1.4.4.1. Market Forecast,
2021 - 2029
9.2.1.4.5.
Latin America
9.2.1.4.5.1. Market Forecast,
2021 - 2029
9.2.2. Acute HDV superinfection
of a chronic HBV carrier
9.2.2.1.
Definition
9.2.2.2.
Market Forecast, 2021 - 2029
9.2.2.3.
Compound Annual Growth Rate
(CAGR)
9.2.2.4.
Regional Bifurcation
9.2.2.4.1.
North America
9.2.2.4.1.1. Market Forecast,
2021 - 2029
9.2.2.4.2.
Europe
9.2.2.4.2.1. Market Forecast,
2021 - 2029
9.2.2.4.3.
Asia Pacific
9.2.2.4.3.1. Market Forecast,
2021 - 2029
9.2.2.4.4.
Middle East and Africa
9.2.2.4.4.1. Market Forecast,
2021 - 2029
9.2.2.4.5.
Latin America
9.2.2.4.5.1. Market Forecast,
2021 - 2029
9.2.3. Chronic HDV infection
9.2.3.1.
Definition
9.2.3.2.
Market Forecast, 2021 - 2029
9.2.3.3.
Compound Annual Growth Rate
(CAGR)
9.2.3.4.
Regional Bifurcation
9.2.3.4.1.
North America
9.2.3.4.1.1. Market Forecast,
2021 - 2029
9.2.3.4.2.
Europe
9.2.3.4.2.1. Market Forecast,
2021 - 2029
9.2.3.4.3.
Asia Pacific
9.2.3.4.3.1. Market Forecast,
2021 - 2029
9.2.3.4.4.
Middle East and Africa
9.2.3.4.4.1. Market Forecast,
2021 - 2029
9.2.3.4.5.
Latin America
9.2.3.4.5.1. Market Forecast,
2021 - 2029
9.3. Key Segment for
Channeling Investments
9.3.1. By Clinical Entities
10. Global Hepatitis D Virus (HDV) Infection Market Analysis and Forecasts, 2021 – 2029
10.1. Overview
10.2. Global Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
10.2.1. Below 20 years
10.2.1.1.
Definition
10.2.1.2.
Market Forecast, 2021 - 2029
10.2.1.3.
Compound Annual Growth Rate
(CAGR)
10.2.1.4.
Regional Bifurcation
10.2.1.4.1.
North America
10.2.1.4.1.1. Market Forecast,
2021 - 2029
10.2.1.4.2.
Europe
10.2.1.4.2.1. Market Forecast,
2021 - 2029
10.2.1.4.3.
Asia Pacific
10.2.1.4.3.1. Market Forecast,
2021 - 2029
10.2.1.4.4.
Middle East and Africa
10.2.1.4.4.1. Market Forecast,
2021 - 2029
10.2.1.4.5.
Latin America
10.2.1.4.5.1. Market Forecast,
2021 - 2029
10.2.2. 21 – 35 years
10.2.2.1.
Definition
10.2.2.2.
Market Forecast, 2021 - 2029
10.2.2.3.
Compound Annual Growth Rate
(CAGR)
10.2.2.4.
Regional Bifurcation
10.2.2.4.1.
North America
10.2.2.4.1.1. Market Forecast,
2021 - 2029
10.2.2.4.2.
Europe
10.2.2.4.2.1. Market Forecast,
2021 - 2029
10.2.2.4.3.
Asia Pacific
10.2.2.4.3.1. Market Forecast,
2021 - 2029
10.2.2.4.4.
Middle East and Africa
10.2.2.4.4.1. Market Forecast,
2021 - 2029
10.2.2.4.5.
Latin America
10.2.2.4.5.1. Market Forecast,
2021 - 2029
10.2.3. 36 – 50 Years
10.2.3.1.
Definition
10.2.3.2.
Market Forecast, 2021 - 2029
10.2.3.3.
Compound Annual Growth Rate
(CAGR)
10.2.3.4.
Regional Bifurcation
10.2.3.4.1.
North America
10.2.3.4.1.1. Market Forecast,
2021 - 2029
10.2.3.4.2.
Europe
10.2.3.4.2.1. Market Forecast,
2021 - 2029
10.2.3.4.3.
Asia Pacific
10.2.3.4.3.1. Market Forecast,
2021 - 2029
10.2.3.4.4.
Middle East and Africa
10.2.3.4.4.1. Market Forecast,
2021 - 2029
10.2.3.4.5.
Latin America
10.2.3.4.5.1. Market Forecast,
2021 - 2029
10.2.4. Above 50
10.2.4.1.
Definition
10.2.4.2.
Market Forecast, 2021 - 2029
10.2.4.3.
Compound Annual Growth Rate
(CAGR)
10.2.4.4.
Regional Bifurcation
10.2.4.4.1.
North America
10.2.4.4.1.1. Market Forecast,
2021 - 2029
10.2.4.4.2.
Europe
10.2.4.4.2.1. Market Forecast,
2021 - 2029
10.2.4.4.3.
Asia Pacific
10.2.4.4.3.1. Market Forecast,
2021 - 2029
10.2.4.4.4.
Middle East and Africa
10.2.4.4.4.1. Market Forecast,
2021 - 2029
10.2.4.4.5.
Latin America
10.2.4.4.5.1. Market Forecast,
2021 - 2029
10.3. Key Segment for
Channeling Investments
10.3.1. By Age
11. Global Hepatitis D Virus (HDV) Infection Market Analysis and Forecasts, 2021 – 2029
11.1. Overview
11.2. Global Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
11.2.1. Hospitals
11.2.1.1.
Definition
11.2.1.2.
Market Forecast, 2021 - 2029
11.2.1.3.
Compound Annual Growth Rate
(CAGR)
11.2.1.4.
Regional Bifurcation
11.2.1.4.1.
North America
11.2.1.4.1.1. Market Forecast,
2021 - 2029
11.2.1.4.2.
Europe
11.2.1.4.2.1. Market Forecast,
2021 - 2029
11.2.1.4.3.
Asia Pacific
11.2.1.4.3.1. Market Forecast,
2021 - 2029
11.2.1.4.4.
Middle East and Africa
11.2.1.4.4.1. Market Forecast,
2021 - 2029
11.2.1.4.5.
Latin America
11.2.1.4.5.1. Market Forecast,
2021 - 2029
11.2.2. Speciality Clinics
11.2.2.1.
Definition
11.2.2.2.
Market Forecast, 2021 - 2029
11.2.2.3.
Compound Annual Growth Rate
(CAGR)
11.2.2.4.
Regional Bifurcation
11.2.2.4.1.
North America
11.2.2.4.1.1. Market Forecast,
2021 - 2029
11.2.2.4.2.
Europe
11.2.2.4.2.1. Market Forecast,
2021 - 2029
11.2.2.4.3.
Asia Pacific
11.2.2.4.3.1. Market Forecast,
2021 - 2029
11.2.2.4.4.
Middle East and Africa
11.2.2.4.4.1. Market Forecast,
2021 - 2029
11.2.2.4.5.
Latin America
11.2.2.4.5.1. Market Forecast,
2021 - 2029
11.2.3. Research Centers
11.2.3.1.
Definition
11.2.3.2.
Market Forecast, 2021 - 2029
11.2.3.3.
Compound Annual Growth Rate
(CAGR)
11.2.3.4.
Regional Bifurcation
11.2.3.4.1.
North America
11.2.3.4.1.1. Market Forecast,
2021 - 2029
11.2.3.4.2.
Europe
11.2.3.4.2.1. Market Forecast,
2021 - 2029
11.2.3.4.3.
Asia Pacific
11.2.3.4.3.1. Market Forecast,
2021 - 2029
11.2.3.4.4.
Middle East and Africa
11.2.3.4.4.1. Market Forecast,
2021 - 2029
11.2.3.4.5.
Latin America
11.2.3.4.5.1. Market Forecast,
2021 - 2029
11.3. Key Segment for
Channeling Investments
11.3.1. By Application
12. North America Hepatitis D Virus (HDV) Infection Market Analysis and Forecasts, 2021 - 2029
12.1. Overview
12.1.1. North America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn)
12.2. North America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Trails
12.2.1. Pre-Clinical and Phase
I
12.2.2. Phase II
12.2.3. Phase III
12.3. North America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Entities
12.3.1. Acute HBV/HDV
coinfection
12.3.2. Acute HDV
superinfection of a chronic HBV carrier
12.3.3. Chronic HDV infection
12.4. North America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Age
12.4.1. Below 20 years
12.4.2. 21 – 35 years
12.4.3. 36 – 50 Years
12.4.4. Above 50
12.5. North America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Application
12.5.1. Hospitals
12.5.2. Speciality Clinics
12.5.3. Research Centers
12.6. North America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Country
12.6.1. U.S
12.6.1.1.
U.S Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
12.6.1.1.1.
Pre-Clinical and Phase I
12.6.1.1.2.
Phase II
12.6.1.1.3.
Phase III
12.6.1.2.
U.S Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
12.6.1.2.1.
Acute HBV/HDV coinfection
12.6.1.2.2.
Acute HDV superinfection of a
chronic HBV carrier
12.6.1.2.3.
Chronic HDV infection
12.6.1.3.
U.S Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
12.6.1.3.1.
Below 20 years
12.6.1.3.2.
21 – 35 years
12.6.1.3.3.
36 – 50 Years
12.6.1.3.4.
Above 50
12.6.1.4.
U.S Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.1.4.1.
Hospitals
12.6.1.4.2.
Speciality Clinics
12.6.1.4.3.
Research Centers
12.6.2. Canada
12.6.2.1.
Canada Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
12.6.2.1.1.
Pre-Clinical and Phase I
12.6.2.1.2.
Phase II
12.6.2.1.3.
Phase III
12.6.2.2.
Canada Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
12.6.2.2.1.
Acute HBV/HDV coinfection
12.6.2.2.2.
Acute HDV superinfection of a
chronic HBV carrier
12.6.2.2.3.
Chronic HDV infection
12.6.2.3.
Canada Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
12.6.2.3.1.
Below 20 years
12.6.2.3.2.
21 – 35 years
12.6.2.3.3.
36 – 50 Years
12.6.2.3.4.
Above 50
12.6.2.4.
Canada Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.2.4.1.
Hospitals
12.6.2.4.2.
Speciality Clinics
12.6.2.4.3.
Research Centers
12.6.3. Mexico
12.6.3.1.
Mexico Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
12.6.3.1.1.
Pre-Clinical and Phase I
12.6.3.1.2.
Phase II
12.6.3.1.3.
Phase III
12.6.3.2.
Mexico Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
12.6.3.2.1.
Acute HBV/HDV coinfection
12.6.3.2.2.
Acute HDV superinfection of a
chronic HBV carrier
12.6.3.2.3.
Chronic HDV infection
12.6.3.3.
Mexico Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
12.6.3.3.1.
Below 20 years
12.6.3.3.2.
21 – 35 years
12.6.3.3.3.
36 – 50 Years
12.6.3.3.4.
Above 50
12.6.3.4.
Mexico Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
12.6.3.4.1.
Hospitals
12.6.3.4.2.
Speciality Clinics
12.6.3.4.3.
Research Centers
12.6.4. Rest of North America
12.6.4.1.
Rest of North America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Trails
12.6.4.1.1.
Pre-Clinical and Phase I
12.6.4.1.2.
Phase II
12.6.4.1.3.
Phase III
12.6.4.2.
Rest of North America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Entities
12.6.4.2.1.
Acute HBV/HDV coinfection
12.6.4.2.2.
Acute HDV superinfection of a chronic
HBV carrier
12.6.4.2.3.
Chronic HDV infection
12.6.4.3.
Rest of North America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Age
12.6.4.3.1.
Below 20 years
12.6.4.3.2.
21 – 35 years
12.6.4.3.3.
36 – 50 Years
12.6.4.3.4.
Above 50
12.6.4.4.
Rest of North America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Application
12.6.4.4.1.
Hospitals
12.6.4.4.2.
Speciality Clinics
12.6.4.4.3.
Research Centers
12.7. Key Segment for
Channeling Investments
12.7.1. By Country
12.7.2. By Clinical Trails
12.7.3. By Clinical Entities
12.7.4. By Age
12.7.5. By Application
13. Europe Hepatitis D Virus (HDV) Infection Market Analysis and Forecasts, 2021 - 2029
13.1. Overview
13.1.1. Europe Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn)
13.2. Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
13.2.1. Pre-Clinical and Phase
I
13.2.2. Phase II
13.2.3. Phase III
13.3. Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
13.3.1. Acute HBV/HDV
coinfection
13.3.2. Acute HDV
superinfection of a chronic HBV carrier
13.3.3. Chronic HDV infection
13.4. Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
13.4.1. Below 20 years
13.4.2. 21 – 35 years
13.4.3. 36 – 50 Years
13.4.4. Above 50
13.5. Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
13.5.1. Hospitals
13.5.2. Speciality Clinics
13.5.3. Research Centers
13.6. Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.1. France
13.6.1.1.
France Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
13.6.1.1.1.
Pre-Clinical and Phase I
13.6.1.1.2.
Phase II
13.6.1.1.3.
Phase III
13.6.1.2.
France Hepatitis D Virus (HDV) Infection Market Revenue (US$ Mn) and Forecasts, By
Clinical Entities
13.6.1.2.1.
Acute HBV/HDV coinfection
13.6.1.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.1.2.3.
Chronic HDV infection
13.6.1.3.
France Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
13.6.1.3.1.
Below 20 years
13.6.1.3.2.
21 – 35 years
13.6.1.3.3.
36 – 50 Years
13.6.1.3.4.
Above 50
13.6.1.4.
France Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.1.4.1.
Hospitals
13.6.1.4.2.
Speciality Clinics
13.6.1.4.3.
Research Centers
13.6.2. The UK
13.6.2.1.
The UK Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
13.6.2.1.1.
Pre-Clinical and Phase I
13.6.2.1.2.
Phase II
13.6.2.1.3.
Phase III
13.6.2.2.
The UK Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
13.6.2.2.1.
Acute HBV/HDV coinfection
13.6.2.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.2.2.3.
Chronic HDV infection
13.6.2.3.
The UK Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
13.6.2.3.1.
Below 20 years
13.6.2.3.2.
21 – 35 years
13.6.2.3.3.
36 – 50 Years
13.6.2.3.4.
Above 50
13.6.2.4.
The UK Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.2.4.1.
Hospitals
13.6.2.4.2.
Speciality Clinics
13.6.2.4.3.
Research Centers
13.6.3. Spain
13.6.3.1.
Spain Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
13.6.3.1.1.
Pre-Clinical and Phase I
13.6.3.1.2.
Phase II
13.6.3.1.3.
Phase III
13.6.3.2.
Spain Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
13.6.3.2.1.
Acute HBV/HDV coinfection
13.6.3.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.3.2.3.
Chronic HDV infection
13.6.3.3.
Spain Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
13.6.3.3.1.
Below 20 years
13.6.3.3.2.
21 – 35 years
13.6.3.3.3.
36 – 50 Years
13.6.3.3.4.
Above 50
13.6.3.4.
Spain Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.3.4.1.
Hospitals
13.6.3.4.2.
Speciality Clinics
13.6.3.4.3.
Research Centers
13.6.4. Germany
13.6.4.1.
Germany Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
13.6.4.1.1.
Pre-Clinical and Phase I
13.6.4.1.2.
Phase II
13.6.4.1.3.
Phase III
13.6.4.2.
Germany Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
13.6.4.2.1.
Acute HBV/HDV coinfection
13.6.4.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.4.2.3.
Chronic HDV infection
13.6.4.3.
Germany Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
13.6.4.3.1.
Below 20 years
13.6.4.3.2.
21 – 35 years
13.6.4.3.3.
36 – 50 Years
13.6.4.3.4.
Above 50
13.6.4.4.
Germany Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.4.4.1.
Hospitals
13.6.4.4.2.
Speciality Clinics
13.6.4.4.3.
Research Centers
13.6.5. Italy
13.6.5.1.
Italy Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
13.6.5.1.1.
Pre-Clinical and Phase I
13.6.5.1.2.
Phase II
13.6.5.1.3.
Phase III
13.6.5.2.
Italy Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
13.6.5.2.1.
Acute HBV/HDV coinfection
13.6.5.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.5.2.3.
Chronic HDV infection
13.6.5.3.
Italy Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
13.6.5.3.1.
Below 20 years
13.6.5.3.2.
21 – 35 years
13.6.5.3.3.
36 – 50 Years
13.6.5.3.4.
Above 50
13.6.5.4.
Italy Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
13.6.5.4.1.
Hospitals
13.6.5.4.2.
Speciality Clinics
13.6.5.4.3.
Research Centers
13.6.6. Nordic Countries
13.6.6.1.
Nordic Countries Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Trails
13.6.6.1.1.
Pre-Clinical and Phase I
13.6.6.1.2.
Phase II
13.6.6.1.3.
Phase III
13.6.6.2.
Nordic Countries Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Entities
13.6.6.2.1.
Acute HBV/HDV coinfection
13.6.6.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.6.2.3.
Chronic HDV infection
13.6.6.3.
Nordic Countries Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Age
13.6.6.3.1.
Below 20 years
13.6.6.3.2.
21 – 35 years
13.6.6.3.3.
36 – 50 Years
13.6.6.3.4.
Above 50
13.6.6.4.
Nordic Countries Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Application
13.6.6.4.1.
Hospitals
13.6.6.4.2.
Speciality Clinics
13.6.6.4.3.
Research Centers
13.6.6.5.
Nordic Countries Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Country
13.6.6.5.1.
Denmark
13.6.6.5.2.
Finland
13.6.6.5.3.
Iceland
13.6.6.5.4.
Sweden
13.6.6.5.5.
Norway
13.6.7. Benelux Union
13.6.7.1.
Benelux Union Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
13.6.7.1.1.
Pre-Clinical and Phase I
13.6.7.1.2.
Phase II
13.6.7.1.3.
Phase III
13.6.7.2.
Benelux Union Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
13.6.7.2.1.
Acute HBV/HDV coinfection
13.6.7.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.7.2.3.
Chronic HDV infection
13.6.7.3.
Benelux Union Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
13.6.7.3.1.
Below 20 years
13.6.7.3.2.
21 – 35 years
13.6.7.3.3.
36 – 50 Years
13.6.7.3.4.
Above 50
13.6.7.4.
Benelux Union Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.7.4.1.
Hospitals
13.6.7.4.2.
Speciality Clinics
13.6.7.4.3.
Research Centers
13.6.7.5.
Benelux Union Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Country
13.6.7.5.1.
Belgium
13.6.7.5.2.
The Netherlands
13.6.7.5.3.
Luxembourg
13.6.8. Rest of Europe
13.6.8.1.
Rest of Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
13.6.8.1.1.
Pre-Clinical and Phase I
13.6.8.1.2.
Phase II
13.6.8.1.3.
Phase III
13.6.8.2.
Rest of Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
13.6.8.2.1.
Acute HBV/HDV coinfection
13.6.8.2.2.
Acute HDV superinfection of a
chronic HBV carrier
13.6.8.2.3.
Chronic HDV infection
13.6.8.3.
Rest of Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
13.6.8.3.1.
Below 20 years
13.6.8.3.2.
21 – 35 years
13.6.8.3.3.
36 – 50 Years
13.6.8.3.4.
Above 50
13.6.8.4.
Rest of Europe Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
13.6.8.4.1.
Hospitals
13.6.8.4.2.
Speciality Clinics
13.6.8.4.3.
Research Centers
13.7. Key Segment for
Channeling Investments
13.7.1. By Country
13.7.2. By Clinical Trails
13.7.3. By Clinical Entities
13.7.4. By Age
13.7.5. By Application
14. Asia Pacific Hepatitis D Virus (HDV) Infection Market Analysis and Forecasts, 2021 - 2029
14.1. Overview
14.1.1. Asia Pacific Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn)
14.2. Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Trails
14.2.1. Pre-Clinical and Phase
I
14.2.2. Phase II
14.2.3. Phase III
14.3. Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Entities
14.3.1. Acute HBV/HDV
coinfection
14.3.2. Acute HDV
superinfection of a chronic HBV carrier
14.3.3. Chronic HDV infection
14.4. Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Age
14.4.1. Below 20 years
14.4.2. 21 – 35 years
14.4.3. 36 – 50 Years
14.4.4. Above 50
14.5. Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Application
14.5.1. Hospitals
14.5.2. Speciality Clinics
14.5.3. Research Centers
14.6. Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Country
14.6.1. China
14.6.1.1.
China Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
14.6.1.1.1.
Pre-Clinical and Phase I
14.6.1.1.2.
Phase II
14.6.1.1.3.
Phase III
14.6.1.2.
China Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
14.6.1.2.1.
Acute HBV/HDV coinfection
14.6.1.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.1.2.3.
Chronic HDV infection
14.6.1.3.
China Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
14.6.1.3.1.
Below 20 years
14.6.1.3.2.
21 – 35 years
14.6.1.3.3.
36 – 50 Years
14.6.1.3.4.
Above 50
14.6.1.4.
China Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.1.4.1.
Hospitals
14.6.1.4.2.
Speciality Clinics
14.6.1.4.3.
Research Centers
14.6.2. Japan
14.6.2.1.
Japan Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
14.6.2.1.1.
Pre-Clinical and Phase I
14.6.2.1.2.
Phase II
14.6.2.1.3.
Phase III
14.6.2.2.
Japan Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
14.6.2.2.1.
Acute HBV/HDV coinfection
14.6.2.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.2.2.3.
Chronic HDV infection
14.6.2.3.
Japan Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
14.6.2.3.1.
Below 20 years
14.6.2.3.2.
21 – 35 years
14.6.2.3.3.
36 – 50 Years
14.6.2.3.4.
Above 50
14.6.2.4.
Japan Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.2.4.1.
Hospitals
14.6.2.4.2.
Speciality Clinics
14.6.2.4.3.
Research Centers
14.6.3. India
14.6.3.1.
India Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
14.6.3.1.1.
Pre-Clinical and Phase I
14.6.3.1.2.
Phase II
14.6.3.1.3.
Phase III
14.6.3.2.
India Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
14.6.3.2.1.
Acute HBV/HDV coinfection
14.6.3.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.3.2.3.
Chronic HDV infection
14.6.3.3.
India Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
14.6.3.3.1.
Below 20 years
14.6.3.3.2.
21 – 35 years
14.6.3.3.3.
36 – 50 Years
14.6.3.3.4.
Above 50
14.6.3.4.
India Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
14.6.3.4.1.
Hospitals
14.6.3.4.2.
Speciality Clinics
14.6.3.4.3.
Research Centers
14.6.4. New Zealand
14.6.4.1.
New Zealand Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
14.6.4.1.1.
Pre-Clinical and Phase I
14.6.4.1.2.
Phase II
14.6.4.1.3.
Phase III
14.6.4.2.
New Zealand Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
14.6.4.2.1.
Acute HBV/HDV coinfection
14.6.4.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.4.2.3.
Chronic HDV infection
14.6.4.3.
New Zealand Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
14.6.4.3.1.
Below 20 years
14.6.4.3.2.
21 – 35 years
14.6.4.3.3.
36 – 50 Years
14.6.4.3.4.
Above 50
14.6.4.4.
New Zealand Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.4.4.1.
Hospitals
14.6.4.4.2.
Speciality Clinics
14.6.4.4.3.
Research Centers
14.6.5. Australia
14.6.5.1.
Australia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
14.6.5.1.1.
Pre-Clinical and Phase I
14.6.5.1.2.
Phase II
14.6.5.1.3.
Phase III
14.6.5.2.
Australia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
14.6.5.2.1.
Acute HBV/HDV coinfection
14.6.5.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.5.2.3.
Chronic HDV infection
14.6.5.3.
Australia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
14.6.5.3.1.
Below 20 years
14.6.5.3.2.
21 – 35 years
14.6.5.3.3.
36 – 50 Years
14.6.5.3.4.
Above 50
14.6.5.4.
Australia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.5.4.1.
Hospitals
14.6.5.4.2.
Speciality Clinics
14.6.5.4.3.
Research Centers
14.6.6. South Korea
14.6.6.1.
South Korea Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
14.6.6.1.1.
Pre-Clinical and Phase I
14.6.6.1.2.
Phase II
14.6.6.1.3.
Phase III
14.6.6.2.
South Korea Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
14.6.6.2.1.
Acute HBV/HDV coinfection
14.6.6.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.6.2.3.
Chronic HDV infection
14.6.6.3.
South Korea Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
14.6.6.3.1.
Below 20 years
14.6.6.3.2.
21 – 35 years
14.6.6.3.3.
36 – 50 Years
14.6.6.3.4.
Above 50
14.6.6.4.
South Korea Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.6.4.1.
Hospitals
14.6.6.4.2.
Speciality Clinics
14.6.6.4.3.
Research Centers
14.6.7. Southeast Asia
14.6.7.1.
Southeast Asia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
14.6.7.1.1.
Pre-Clinical and Phase I
14.6.7.1.2.
Phase II
14.6.7.1.3.
Phase III
14.6.7.2.
Southeast Asia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
14.6.7.2.1.
Acute HBV/HDV coinfection
14.6.7.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.7.2.3.
Chronic HDV infection
14.6.7.3.
Southeast Asia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
14.6.7.3.1.
Below 20 years
14.6.7.3.2.
21 – 35 years
14.6.7.3.3.
36 – 50 Years
14.6.7.3.4.
Above 50
14.6.7.4.
Southeast Asia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
14.6.7.4.1.
Hospitals
14.6.7.4.2.
Speciality Clinics
14.6.7.4.3.
Research Centers
14.6.7.5.
Southeast Asia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Country
14.6.7.5.1.
Indonesia
14.6.7.5.2.
Thailand
14.6.7.5.3.
Malaysia
14.6.7.5.4.
Singapore
14.6.7.5.5.
Rest of Southeast Asia
14.6.8. Rest of Asia Pacific
14.6.8.1.
Rest of Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Trails
14.6.8.1.1.
Pre-Clinical and Phase I
14.6.8.1.2.
Phase II
14.6.8.1.3.
Phase III
14.6.8.2.
Rest of Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Entities
14.6.8.2.1.
Acute HBV/HDV coinfection
14.6.8.2.2.
Acute HDV superinfection of a
chronic HBV carrier
14.6.8.2.3.
Chronic HDV infection
14.6.8.3.
Rest of Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Age
14.6.8.3.1.
Below 20 years
14.6.8.3.2.
21 – 35 years
14.6.8.3.3.
36 – 50 Years
14.6.8.3.4.
Above 50
14.6.8.4.
Rest of Asia Pacific Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Application
14.6.8.4.1.
Hospitals
14.6.8.4.2.
Speciality Clinics
14.6.8.4.3.
Research Centers
14.7. Key Segment for
Channeling Investments
14.7.1. By Country
14.7.2. By Clinical Trails
14.7.3. By Clinical Entities
14.7.4. By Age
14.7.5. By Application
15. Middle East and Africa Hepatitis D Virus (HDV) Infection Market Analysis and Forecasts, 2021 - 2029
15.1. Overview
15.1.1. Middle East and Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn)
15.2. Middle East and Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Clinical Trails
15.2.1. Pre-Clinical and Phase
I
15.2.2. Phase II
15.2.3. Phase III
15.3. Middle East and Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Clinical Entities
15.3.1. Acute HBV/HDV
coinfection
15.3.2. Acute HDV
superinfection of a chronic HBV carrier
15.3.3. Chronic HDV infection
15.4. Middle East and Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Age
15.4.1. Below 20 years
15.4.2. 21 – 35 years
15.4.3. 36 – 50 Years
15.4.4. Above 50
15.5. Middle East and Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Application
15.5.1. Hospitals
15.5.2. Speciality Clinics
15.5.3. Research Centers
15.6. Middle East and Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Country
15.6.1. Saudi Arabia
15.6.1.1.
Saudi Arabia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
15.6.1.1.1.
Pre-Clinical and Phase I
15.6.1.1.2.
Phase II
15.6.1.1.3.
Phase III
15.6.1.2.
Saudi Arabia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
15.6.1.2.1.
Acute HBV/HDV coinfection
15.6.1.2.2.
Acute HDV superinfection of a
chronic HBV carrier
15.6.1.2.3.
Chronic HDV infection
15.6.1.3.
Saudi Arabia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
15.6.1.3.1.
Below 20 years
15.6.1.3.2.
21 – 35 years
15.6.1.3.3.
36 – 50 Years
15.6.1.3.4.
Above 50
15.6.1.4.
Saudi Arabia Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.1.4.1.
Hospitals
15.6.1.4.2.
Speciality Clinics
15.6.1.4.3.
Research Centers
15.6.2. UAE
15.6.2.1.
UAE Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
15.6.2.1.1.
Pre-Clinical and Phase I
15.6.2.1.2.
Phase II
15.6.2.1.3.
Phase III
15.6.2.2.
UAE Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
15.6.2.2.1.
Acute HBV/HDV coinfection
15.6.2.2.2.
Acute HDV superinfection of a
chronic HBV carrier
15.6.2.2.3.
Chronic HDV infection
15.6.2.3.
UAE Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
15.6.2.3.1.
Below 20 years
15.6.2.3.2.
21 – 35 years
15.6.2.3.3.
36 – 50 Years
15.6.2.3.4.
Above 50
15.6.2.4.
UAE Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.2.4.1.
Hospitals
15.6.2.4.2.
Speciality Clinics
15.6.2.4.3.
Research Centers
15.6.3. Egypt
15.6.3.1.
Egypt Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
15.6.3.1.1.
Pre-Clinical and Phase I
15.6.3.1.2.
Phase II
15.6.3.1.3.
Phase III
15.6.3.2.
Egypt Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
15.6.3.2.1.
Acute HBV/HDV coinfection
15.6.3.2.2.
Acute HDV superinfection of a
chronic HBV carrier
15.6.3.2.3.
Chronic HDV infection
15.6.3.3.
Egypt Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
15.6.3.3.1.
Below 20 years
15.6.3.3.2.
21 – 35 years
15.6.3.3.3.
36 – 50 Years
15.6.3.3.4.
Above 50
15.6.3.4.
Egypt Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.3.4.1.
Hospitals
15.6.3.4.2.
Speciality Clinics
15.6.3.4.3.
Research Centers
15.6.4. Kuwait
15.6.4.1.
Kuwait Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
15.6.4.1.1.
Pre-Clinical and Phase I
15.6.4.1.2.
Phase II
15.6.4.1.3.
Phase III
15.6.4.2.
Kuwait Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
15.6.4.2.1.
Acute HBV/HDV coinfection
15.6.4.2.2.
Acute HDV superinfection of a
chronic HBV carrier
15.6.4.2.3.
Chronic HDV infection
15.6.4.3.
Kuwait Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
15.6.4.3.1.
Below 20 years
15.6.4.3.2.
21 – 35 years
15.6.4.3.3.
36 – 50 Years
15.6.4.3.4.
Above 50
15.6.4.4.
Kuwait Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
15.6.4.4.1.
Hospitals
15.6.4.4.2.
Speciality Clinics
15.6.4.4.3.
Research Centers
15.6.5. South Africa
15.6.5.1.
South Africa Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
15.6.5.1.1.
Pre-Clinical and Phase I
15.6.5.1.2.
Phase II
15.6.5.1.3.
Phase III
15.6.5.2.
South Africa Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
15.6.5.2.1.
Acute HBV/HDV coinfection
15.6.5.2.2.
Acute HDV superinfection of a
chronic HBV carrier
15.6.5.2.3.
Chronic HDV infection
15.6.5.3.
South Africa Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
15.6.5.3.1.
Below 20 years
15.6.5.3.2.
21 – 35 years
15.6.5.3.3.
36 – 50 Years
15.6.5.3.4.
Above 50
15.6.5.4.
South Africa Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
15.6.5.4.1.
Hospitals
15.6.5.4.2.
Speciality Clinics
15.6.5.4.3.
Research Centers
15.6.6. Rest of Middle East
& Africa
15.6.6.1.
Rest of Middle East & Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Clinical Trails
15.6.6.1.1.
Pre-Clinical and Phase I
15.6.6.1.2.
Phase II
15.6.6.1.3.
Phase III
15.6.6.2.
Rest of Middle East & Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Clinical Entities
15.6.6.2.1.
Acute HBV/HDV coinfection
15.6.6.2.2.
Acute HDV superinfection of a
chronic HBV carrier
15.6.6.2.3.
Chronic HDV infection
15.6.6.3.
Rest of Middle East & Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Age
15.6.6.3.1.
Below 20 years
15.6.6.3.2.
21 – 35 years
15.6.6.3.3.
36 – 50 Years
15.6.6.3.4.
Above 50
15.6.6.4.
Rest of Middle East & Africa
Hepatitis D Virus (HDV) Infection Market
Revenue (US$ Mn) and Forecasts, By Application
15.6.6.4.1.
Hospitals
15.6.6.4.2.
Speciality Clinics
15.6.6.4.3.
Research Centers
15.7. Key Segment for
Channeling Investments
15.7.1. By Country
15.7.2. By Clinical Trails
15.7.3. By Clinical Entities
15.7.4. By Age
15.7.5. By Application
16. Latin America Hepatitis D Virus (HDV) Infection Market Analysis and Forecasts, 2021 - 2029
16.1. Overview
16.1.1. Latin America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn)
16.2. Latin America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Trails
16.2.1. Pre-Clinical and Phase
I
16.2.2. Phase II
16.2.3. Phase III
16.3. Latin America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Entities
16.3.1. Acute HBV/HDV
coinfection
16.3.2. Acute HDV
superinfection of a chronic HBV carrier
16.3.3. Chronic HDV infection
16.4. Latin America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Age
16.4.1. Below 20 years
16.4.2. 21 – 35 years
16.4.3. 36 – 50 Years
16.4.4. Above 50
16.5. Latin America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Application
16.5.1. Hospitals
16.5.2. Speciality Clinics
16.5.3. Research Centers
16.6. Latin America Hepatitis D
Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Country
16.6.1. Brazil
16.6.1.1.
Brazil Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Trails
16.6.1.1.1.
Pre-Clinical and Phase I
16.6.1.1.2.
Phase II
16.6.1.1.3.
Phase III
16.6.1.2.
Brazil Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Clinical Entities
16.6.1.2.1.
Acute HBV/HDV coinfection
16.6.1.2.2.
Acute HDV superinfection of a
chronic HBV carrier
16.6.1.2.3.
Chronic HDV infection
16.6.1.3.
Brazil Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Age
16.6.1.3.1.
Below 20 years
16.6.1.3.2.
21 – 35 years
16.6.1.3.3.
36 – 50 Years
16.6.1.3.4.
Above 50
16.6.1.4.
Brazil Hepatitis D Virus (HDV)
Infection Market Revenue (US$ Mn) and
Forecasts, By Application
16.6.1.4.1.
Hospitals
16.6.1.4.2.
Speciality Clinics
16.6.1.4.3.
Research Centers
16.6.2. Argentina
16.6.2.1.
Argentina Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Trails
16.6.2.1.1.
Pre-Clinical and Phase I
16.6.2.1.2.
Phase II
16.6.2.1.3.
Phase III
16.6.2.2.
Argentina Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Clinical Entities
16.6.2.2.1.
Acute HBV/HDV coinfection
16.6.2.2.2.
Acute HDV superinfection of a
chronic HBV carrier
16.6.2.2.3.
Chronic HDV infection
16.6.2.3.
Argentina Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Age
16.6.2.3.1.
Below 20 years
16.6.2.3.2.
21 – 35 years
16.6.2.3.3.
36 – 50 Years
16.6.2.3.4.
Above 50
16.6.2.4.
Argentina Hepatitis D Virus
(HDV) Infection Market Revenue (US$ Mn)
and Forecasts, By Application
16.6.2.4.1.
Hospitals
16.6.2.4.2.
Speciality Clinics
16.6.2.4.3.
Research Centers
16.6.3. Rest of Latin America
16.6.3.1.
Rest of Latin America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Trails
16.6.3.1.1.
Pre-Clinical and Phase I
16.6.3.1.2.
Phase II
16.6.3.1.3.
Phase III
16.6.3.2.
Rest of Latin America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Clinical Entities
16.6.3.2.1.
Acute HBV/HDV coinfection
16.6.3.2.2.
Acute HDV superinfection of a
chronic HBV carrier
16.6.3.2.3.
Chronic HDV infection
16.6.3.3.
Rest of Latin America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Age
16.6.3.3.1.
Below 20 years
16.6.3.3.2.
21 – 35 years
16.6.3.3.3.
36 – 50 Years
16.6.3.3.4.
Above 50
16.6.3.4.
Rest of Latin America Hepatitis
D Virus (HDV) Infection Market Revenue
(US$ Mn) and Forecasts, By Application
16.6.3.4.1.
Hospitals
16.6.3.4.2.
Speciality Clinics
16.6.3.4.3.
Research Centers
16.7. Key Segment for
Channeling Investments
16.7.1. By Country
16.7.2. By Clinical Trails
16.7.3. By Clinical Entities
16.7.4. By Age
16.7.5. By Application
17. Competitive Benchmarking
17.1. Brand Benchmarking
17.2. Global Presence and
Growth Strategies
17.2.1. Mergers and
Acquisitions
17.2.2. Product Launches
17.2.3. Investments Trends
17.2.4. R&D Initiatives
18. Player Profiles
18.1. Alnylam Pharmaceuticals,
Inc.
18.1.1. Company Details
18.1.2. Company Overview
18.1.3. Product Offerings
18.1.4. Key Developments
18.1.5. Financial Analysis
18.1.6. SWOT Analysis
18.1.7. Business Strategies
18.2. EigerBioPharmaceuticals
18.2.1. Company Details
18.2.2. Company Overview
18.2.3. Product Offerings
18.2.4. Key Developments
18.2.5. Financial Analysis
18.2.6. SWOT Analysis
18.2.7. Business Strategies
18.3. Gilead Sciences, Inc.
18.3.1. Company Details
18.3.2. Company Overview
18.3.3. Product Offerings
18.3.4. Key Developments
18.3.5. Financial Analysis
18.3.6. SWOT Analysis
18.3.7. Business Strategies
18.4. Janssen Global Services,
LLC
18.4.1. Company Details
18.4.2. Company Overview
18.4.3. Product Offerings
18.4.4. Key Developments
18.4.5. Financial Analysis
18.4.6. SWOT Analysis
18.4.7. Business Strategies
18.5. Replicor
18.5.1. Company Details
18.5.2. Company Overview
18.5.3. Product Offerings
18.5.4. Key Developments
18.5.5. Financial Analysis
18.5.6. SWOT Analysis
18.5.7. Business Strategies
18.6. Other Market Participants
19. Key Findings
Note: This ToC is tentative
and can be changed according to the research study conducted during the course
of report completion.
**Exclusive for Multi-User and
Enterprise User.
At Absolute Markets Insights, we are engaged in building both global as well as country specific reports. As a result, the approach taken for deriving the estimation and forecast for a specific country is a bit unique and different in comparison to the global research studies. In this case, we not only study the concerned market factors & trends prevailing in a particular country (from secondary research) but we also tend to calculate the actual market size & forecast from the revenue generated from the market participants involved in manufacturing or distributing the any concerned product. These companies can also be service providers. For analyzing any country specifically, we do consider the growth factors prevailing under the states/cities/county for the same. For instance, if we are analyzing an industry specific to United States, we primarily need to study about the states present under the same(where the product/service has the highest growth). Similar analysis will be followed by other countries. Our scope of the report changes with different markets.
Our research study is mainly implement through a mix of both secondary and primary research. Various sources such as industry magazines, trade journals, and government websites and trade associations are reviewed for gathering precise data. Primary interviews are conducted to validate the market size derived from secondary research. Industry experts, major manufacturers and distributors are contacted for further validation purpose on the current market penetration and growth trends.
Prominent participants in our primary research process include:
- Key Opinion Leaders namely the CEOs, CSOs, VPs, purchasing managers, amongst others
- Research and development participants, distributors/suppliers and subject matter experts
Secondary Research includes data extracted from paid data sources:
- Reuters
- Factiva
- Bloomberg
- One Source
- Hoovers
Research Methodology
Key Inclusions
